Publication: Repurposing Drugs in Oncology (ReDO)—mebendazole as an anti-cancer agent
Open/View Files
Date
2014
Published Version
Journal Title
Journal ISSN
Volume Title
Publisher
Cancer Intelligence
The Harvard community has made this article openly available. Please share how this access benefits you.
Citation
Pantziarka, Pan, Gauthier Bouche, Lydie Meheus, Vidula Sukhatme, and Vikas P Sukhatme. 2014. “Repurposing Drugs in Oncology (ReDO)—mebendazole as an anti-cancer agent.” ecancermedicalscience 8 (1): 443. doi:10.3332/ecancer.2014.443. http://dx.doi.org/10.3332/ecancer.2014.443.
Research Data
Abstract
Mebendazole, a well-known anti-helminthic drug in wide clinical use, has anti-cancer properties that have been elucidated in a broad range of pre-clinical studies across a number of different cancer types. Significantly, there are also two case reports of anti-cancer activity in humans. The data are summarised and discussed in relation to suggested mechanisms of action. Based on the evidence presented, it is proposed that mebendazole would synergise with a range of other drugs, including existing chemotherapeutics, and that further exploration of the potential of mebendazole as an anti-cancer therapeutic is warranted. A number of possible combinations with other drugs are discussed in the Appendix.
Description
Other Available Sources
Keywords
drug repurposing, anti-helminthic, metronomic chemotherapy, cancer, ReDO Project
Terms of Use
This article is made available under the terms and conditions applicable to Other Posted Material (LAA), as set forth at Terms of Service